AGR - Assura Plc
LSE
->
Real Estate
->
REIT—Healthcare Facilities
Warrington,
United Kingdom
Type: Equity
AGR price evolution
AGR
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $1362 | $1384 | $1649 | $1603 |
| Inventory | $531 | $504 | $490 | $495 |
| Total current assets | $3666 | $3323 | $3619 | $3404 |
| Long term investments | ||||
| Property, plant & equipment | $34889 | $34261 | $33527 | $33052 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $46733 | $45689 | $45062 | $43989 |
| Current liabilities | ||||
| Accounts payable | $1808 | $1774 | $1787 | $1924 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $7139 | $6444 | $6208 | $5239 |
| Long term debt | $10839 | $10312 | $9859 | $9984 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $26978 | $25804 | $25186 | $24341 |
| Shareholders' equity | ||||
| Retained earnings | $2059 | $2195 | $2196 | $2015 |
| Other shareholder equity | $31 | $28 | $21 | -$25 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Mar 2022 | 30 Mar 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $243.4 | $46.3 | ||
| Short term investments | ||||
| Net receivables | $1603 | $1745 | $27.2 | $26 |
| Inventory | $495 | $503 | $343 | $262 |
| Total current assets | $3404 | $3210 | $348.5 | $88.7 |
| Long term investments | $3.8 | $0.7 | ||
| Property, plant & equipment | $33184 | $31296 | $2767.6 | $2467.2 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $43989 | $41123 | $3120.5 | $2557.1 |
| Current liabilities | ||||
| Accounts payable | $1924 | $2046 | $2.4 | $5.2 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5239 | $4416 | $75.1 | $66.2 |
| Long term debt | $10037 | $8303 | $1244.4 | $948.7 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $24341 | $21743 | $1330.9 | $1026.4 |
| Shareholders' equity | ||||
| Retained earnings | $2015 | $1910 | $345.1 | $269.2 |
| Other shareholder equity | -$25 | -$180 | $231.2 | $231.2 |
| Total shareholder equity | $1789.6 | $1530.7 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2083 | $1923 | ||
| Cost of revenue | ||||
| Gross Profit | $1626 | $1494 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1372 | $1293 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $19 | $13 | ||
| Interest expense | -$128 | -$117 | ||
| Net income | ||||
| Net income | $205 | $169 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Mar 2022 | 30 Mar 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8309 | $7923 | $136.9 | $120.8 |
| Cost of revenue | $10.4 | $8.8 | ||
| Gross Profit | $5880 | $5467 | $126.5 | $112 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $12.3 | $11.2 | ||
| Total operating expenses | $4950 | $4615 | $22.8 | $20.3 |
| Operating income | $114.1 | $100.5 | ||
| Income from continuing operations | ||||
| EBIT | $114.1 | $100.5 | ||
| Income tax expense | -$9 | $20 | -$0.1 | |
| Interest expense | -$403 | -$41 | -$28.4 | -$25.3 |
| Net income | ||||
| Net income | $786 | $881 | $155.9 | $108.3 |
| Income (for common shares) | $155.9 | $108.3 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$3082 | -$2027 | -$944 | -$3099 |
| Financing activities | ||||
| Dividends paid | -$510 | -$340 | -$170 | -$681 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $2199 | $1433 | $852 | $2202 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $57 | $45 | $61 | $22 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Mar 2022 | 30 Mar 2021 |
|---|---|---|---|---|
| Net income | $155.9 | $108.3 | ||
| Operating activities | ||||
| Depreciation | $0.2 | $0.1 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $94.6 | $77.4 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | -$3.5 | -$0.7 | ||
| Total cash flows from investing | -$3099 | -$2548 | -$293.9 | -$267.5 |
| Financing activities | ||||
| Dividends paid | -$681 | -$681 | -$75.4 | -$61.9 |
| Sale and purchase of stock | ||||
| Net borrowings | $295.9 | $108.1 | ||
| Total cash flows from financing | $2202 | $108 | $396.2 | $218.2 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $22 | -$1405 | $196.9 | $28.1 |
News
Fundamentals
| Market cap | $18.37B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 386.91M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 5.52% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.51 |
| Quick ratio | 0.44 |